MANCHESTER, England, September 9 /PRNewswire/ -- Egg secretions from a worm that causes a deadly human disease may prove useful in gene therapy, according to research presented at the British Pharmaceutical Conference (BPC) in Manchester.

Gene therapy is a method of correcting faulty genes responsible for certain diseases, particularly cancers. It involves using a carrier, or 'vector', to insert new genetic material to mend a faulty gene in the affected cells of the person or 'host'. To achieve this, the vector must be able to survive the host's various defence systems and travel through the cell to its nucleus, which holds the host's genes.

SAN DIEGO, September 8 /PRNewswire/ --

*Weakest Link in Computer Security Strengthened *Innovative UK Company Trumps Industry Giants *Pharma Giant Rolls Out Lanxoma Across Europe

A British developed revolutionary, system-level computer security program Lanxoma (www.lanxoma.com) launched at the prestigious DEMOfall 08 emerging technology conference in San Diego this morning (www.demo.com).

Lanxoma Restricted Access Permission System (RAPS) from Unity Solutions is the first product to address the need for data security from the inside, creating a permanent, digital record that deters abuse, provides accountability and satisfies the most stringent auditing standards.

CALGARY, Canada, September 8 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio.

PRINCETON, New Jersey, September 8 /PRNewswire/ -- Princeton Financial(R) Systems LLC ("Princeton Financial"), a subsidiary of State Street Corporation and a leading provider of portfolio management and accounting solutions for global institutional investors, today announced the signing of a definitive agreement pursuant to which Princeton Financial will acquire all of the outstanding stock of Aquin Components GmbH ("Aquin"), one of Europe's leading software vendors for international asset management and the fund industry and market leader in investment compliance.

PARIS, September 8 /PRNewswire/ -- Alcatel-Lucent (Euronext Paris and NYSE: ALU) today announced it has been placed in the leaders quadrant of the recently published Gartner "Magic Quadrant for Corporate Telephony". For the first time, the report evaluates corporate telephony vendors from a global rather than regional perspective.

The Gartner report recognizes that the market is evolving "from one of proprietary hardware to one of standards-based software" that provides companies the opportunity to "use IP telephony to deliver business benefits across the organization, while consolidating technologies around a common technology or solution provider, or selection of providers and their partners."

BRITISH COLUMBIA, Canada, September 8 /PRNewswire/ --

InNexus Biotechnology Inc. (TSX: IXS.V; OTC Bulletin Board: IXSBF) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces Jeff Morhet, CEO and Chairman, to present during the Wall Street Analyst Forum at the University Club in New York City, Wednesday, September 10, 2008.

CEO and Chairman, Jeff Morhet will provide a company overview, including information about InNexus' unique business strategy, its DXL(TM) technology platform and upcoming company milestones. Investors, venture capitalists, company executives, scientists and other industry leaders will attend the conferences.